65. 原発性免疫不全症候群
[臨床試験数:413,薬物数:581(DrugBank:97),標的遺伝子数:68,標的パスウェイ数:202

Searched query = "Primary immunodeficiency", "X-SCID", "Reticular dysgenesis", "Adenosine deaminase deficiency", "Omenn syndrome", "Purine nucleoside phosphorylase def ... show all
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2007-004088-22-DE
(EUCTR)
14/04/201127/07/2010Efficacy and safety of Fibrinogen Concentrate (Human) for on-demand treatment of acute bleeding in subjects with congenital fibrinogen deficiencyFibrinogen Concentrate (Human) (FCH) - efficacy and safetyEfficacy and safety of Fibrinogen Concentrate (Human) for on-demand treatment of acute bleeding in subjects with congenital fibrinogen deficiencyFibrinogen Concentrate (Human) (FCH) - efficacy and safety Congenital fibrinogen deficiency (afibrinogenemia, severe hypofibrinogenemia)
MedDRA version: 12.0;Level: LLT;Classification code 10016075;Term: Factor I deficiency
Trade Name: Haemocomplettan(R) P 1g/2g
Product Name: Haemocomplettan(R) P
INN or Proposed INN: Fibrinogen (coagulation factorI)
Other descriptive name: HUMAN FIBRINOGEN
CSL Behring GmbHNULLNot RecruitingFemale: yes
Male: yes
23Germany;Italy